Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 0.95% is 96% below its 5-year average of 22.68%, around the middle of its 5-year range (-68.14%–34.43%).
95.10% below its 12-month average of 19.40%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 16.05%.
EBITDA MARGIN
0.95%
EBITDA MARGIN AVG TTM
19.40%
EBITDA MARGIN AVG 3Y
19.69%
EBITDA MARGIN AVG 5Y
22.68%
EBITDA MARGIN AVG 10Y
22.92%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-95.10%
CURRENT VS 3Y AVG
-95.18%
CURRENT VS 5Y AVG
-95.81%
CURRENT VS 10Y AVG
-95.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$21.00B
EBITDA Margin
50.36%
TTM Avg
50.37%
3Y Avg
51.80%
5Y Avg
47.75%
Market Cap
$18.45B
EBITDA Margin
29.84%
TTM Avg
29.78%
3Y Avg
28.27%
5Y Avg
25.91%
Market Cap
$17.09B
EBITDA Margin
22.25%
TTM Avg
22.41%
3Y Avg
21.18%
5Y Avg
20.68%
Market Cap
$15.38B
EBITDA Margin
32.07%
TTM Avg
25.68%
3Y Avg
26.69%
5Y Avg
27.49%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $19.74B | 0.95% | 19.40% | 19.69% | 22.68% |
| STERIS plc (STE)vs › | $19.98B | 26.76% | 25.68% | 26.35% | 25.75% |
| United Therapeutics Corporation (UTHR)vs › | $21.00B | 50.36% | 50.37% | 51.80% | 47.75% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.45B | 29.84% | 29.78% | 28.27% | 25.91% |
| Medpace Holdings, Inc. (MEDP)vs › | $17.09B | 22.25% | 22.41% | 21.18% | 20.68% |
| Revvity, Inc. (RVTY)vs › | $16.00B | 23.07% | 26.75% | 30.05% | 32.80% |
| Solventum Corporation (SOLV)vs › | $15.38B | 32.07% | 25.68% | 26.69% | 27.49% |
| BioNTech SE (BNTX)vs › | $24.13B | -9.29% | -23.11% | 12.60% | 20.38% |
| Exelixis, Inc. (EXEL)vs › | $14.67B | 38.84% | 34.03% | 26.26% | 22.70% |
| Incyte Corporation (INCY)vs › | $25.40B | 27.93% | 16.21% | 17.95% | 14.24% |
Gross Margin
34.8%
EBITDA Margin
0.9%
Operating Margin
-18.6%
Net Margin
-2.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 16.05% |
| 2026-03-31 | 16.96% |
| 2025-12-31 | 13.54% |
| 2025-09-30 | 25.00% |
| 2025-06-30 | 25.44% |
| 2025-03-31 | -68.14% |
| 2024-12-31 | 16.05% |
| 2024-09-30 | 23.88% |
| 2024-06-30 | 14.39% |
| 2024-03-31 | 24.43% |
| 2023-12-31 | 4.95% |
| 2023-09-30 | 28.69% |
| 2023-06-30 | 26.95% |
| 2023-03-31 | 30.30% |
| 2022-12-31 | 17.25% |
| 2022-09-30 | 30.89% |
| 2022-06-30 | 30.87% |
| 2022-03-31 | 34.43% |
| 2021-12-31 | 15.48% |
| 2021-09-30 | 30.30% |
| 2021-06-30 | 27.73% |
| 2021-03-31 | 26.10% |
| 2020-12-31 | 1.99% |
| 2020-09-27 | 26.37% |
| 2020-06-28 | 20.13% |
| 2020-03-29 | 22.90% |
| 2019-12-31 | 25.69% |
| 2019-09-29 | 26.79% |
| 2019-06-29 | 20.93% |
| 2019-03-30 | 21.02% |
| 2018-12-30 | 27.34% |
| 2018-09-29 | 29.30% |
| 2018-06-29 | 24.24% |
| 2018-03-30 | 24.37% |
| 2017-12-30 | 29.22% |
| 2017-09-29 | 25.43% |
| 2017-06-29 | 30.21% |
| 2017-03-30 | 23.65% |
| 2016-12-30 | 24.25% |
| 2016-09-29 | 10.31% |
| 2016-06-29 | 27.89% |
| 2016-03-30 | 18.38% |
| 2015-12-30 | 30.70% |
| 2015-09-29 | 31.86% |
| 2015-06-29 | 22.57% |
| 2015-03-30 | 17.86% |
| 2014-12-30 | 26.94% |
| 2014-09-29 | 30.17% |
| 2014-06-29 | 19.34% |
| 2014-03-30 | 21.81% |
| 2013-12-30 | 22.97% |
| 2013-09-29 | 26.41% |
